Lucid Diagnostics/$LUCD
13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX
About Lucid Diagnostics
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
Ticker
$LUCD
Sector
Primary listing
Employees
72
Headquarters
Website
LUCD Metrics
BasicAdvanced
$112M
-
-$0.98
1.21
-
Price and volume
Market cap
$112M
Beta
1.21
52-week high
$1.80
52-week low
$0.73
Average daily volume
797K
Financial strength
Current ratio
1.15
Quick ratio
1.109
Long term debt to equity
17.578
Total debt to equity
350.458
Interest coverage (TTM)
-2,179.09%
Profitability
EBITDA (TTM)
-47.06
Gross margin (TTM)
-59.27%
Net profit margin (TTM)
-1,267.41%
Operating margin (TTM)
-1,099.54%
Revenue per employee (TTM)
$60,000
Management effectiveness
Return on assets (TTM)
-82.33%
Return on equity (TTM)
-463.56%
Valuation
Price to revenue (TTM)
17.458
Price to book
-2.41
Price to tangible book (TTM)
-2.38
Price to free cash flow (TTM)
-1.738
Free cash flow yield (TTM)
-57.53%
Free cash flow per share (TTM)
-0.633
Growth
Revenue change (TTM)
14.74%
Earnings per share change (TTM)
-19.71%
3-year revenue growth (CAGR)
84.96%
3-year earnings per share growth (CAGR)
-14.04%
What the Analysts think about LUCD
Analyst ratings (Buy, Hold, Sell) for Lucid Diagnostics stock.
LUCD Financial Performance
Revenues and expenses
LUCD Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Lucid Diagnostics stock?
Lucid Diagnostics (LUCD) has a market cap of $112M as of August 25, 2025.
What is the P/E ratio for Lucid Diagnostics stock?
The price to earnings (P/E) ratio for Lucid Diagnostics (LUCD) stock is 0 as of August 25, 2025.
Does Lucid Diagnostics stock pay dividends?
No, Lucid Diagnostics (LUCD) stock does not pay dividends to its shareholders as of August 25, 2025.
When is the next Lucid Diagnostics dividend payment date?
Lucid Diagnostics (LUCD) stock does not pay dividends to its shareholders.
What is the beta indicator for Lucid Diagnostics?
Lucid Diagnostics (LUCD) has a beta rating of 1.21. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.